Abstract
The risk for development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is increased with duration of natalizumab therapy, the presence of JC virus antibodies and a history of prior immunosuppression. Hypogammaglobulinemia has not been described in such patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
